hotspot -WSS

hotspot

author：hotspot 2025-10-01 20:12:37 - browse：84

Gene therapy helped Conner Curran, right, walk, but as the drug fades, his family is supporting scientific efforts to allow him and other boys get a second dose. -- Biotech coverage from STAT — Gene therapy helped Conner Curran (at right) walk, but as the drug fades, his family is supporting scientific efforts to allow him and other boys get a second dose. Courtesy Jess & Chris Curran

In the beginning, Conner Curran ran up the stairs.

It was a miraculous moment for him and his parents, Jess and Chris Curran. Just months before, contractors were in their New York home to install a motorized lift, while Jess tearfully explained that it wasn’t for a grandparent but for their 7-year-old son, who suffered from Duchenne muscular dystrophy and could barely haul himself up the steps.

Then Conner was accepted as the first patient in Pfizer’s Duchenne gene therapy trial. Three weeks later, he could bound to the second floor. Soon, he could walk the two-plus miles to Goldberg’s, a local bagel shop. “I couldn’t do that before,” he told NPR in 2020.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Hearing on Medicare drug price negotiation gets unusually heated

WSS

Emergency workers more likely to restrain Black patients: study

Biotech lab space demand falls sharply

How to protect patients from sexual assault

FDA panel to weigh approval of NurOwn, controversial ALS drug

Hearing on Medicare drug price negotiation gets unusually heated

CommonSpirit Health keeps growing, even as it loses money

focus

hotspot

leisure time

Drug repurposing or repositioning? The language matters

NIH nominee Bertagnolli will get October confirmation hearing

BioMarin wins approval for gene therapy to treat hemophilia A

Intarcia’s device

Sports medicine is finally prioritizing gender equality

Senate HELP committee spars over health care workforce policies

DIEP, the 'gold standard' of breast reconstruction, is under threat

Experts study whether long Covid risk adds up with each reinfection

Peter Hotez and the public health issue of online harassment

What drug price negotiations mean for Medicare Part D

explore

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

AstraZeneca chief proposes a novel edit to the drug pricing bill

It's been 20 years since Dolly the sheep. Where's my clone?

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

Lasker Awards 2023: Winners in biomedical research

Stem cell treatment guidelines are released by FDA

explore

explore

explore

hotspot